background
use
tcell
replet
haploident
hematopoiet
cell
transplant
haplohct
increas
substanti
sinc
introduct
posttranspl
cyclophosphamid
ptci
regimen
limit
data
exist
concern
infecti
complic
haplohct
util
mobil
peripher
blood
pb
hematopoiet
cell
method
retrospect
cohort
studi
includ
adult
patient
institut
undergo
pb
haplohct
ptci
june
june
infect
microbiolog
confirm
invas
fungal
infect
ifi
classifi
proven
probabl
standard
definit
includ
result
total
patient
identifi
median
followup
day
rang
total
episod
infect
record
eightynin
percent
patient
experienc
least
one
infect
median
time
first
infect
day
patient
experienc
least
one
bacteri
viral
ifi
respect
major
bacteri
infect
caus
enter
organ
seven
case
staphylococcu
aureu
infect
record
one
bacteremia
case
cytomegaloviru
cmv
viremia
occur
atrisk
patient
median
time
day
sixteen
patient
develop
cmv
diseas
nineteen
percent
patient
develop
bk
polyomavirusassoci
cystiti
six
patient
experienc
total
seven
ifi
infect
primari
caus
death
patient
secondari
caus
pb
haplohct
patient
high
incid
cmv
viremia
diseas
observ
infect
enter
bacteria
common
fungal
staphylococc
infect
uncommon
studi
need
compar
infecti
complic
haplohct
transplant
modal
altern
graft
sourc
yield
higher
cell
count
obviat
need
donor
anesthesia
hematopoiet
cell
collect
use
pbsc
graft
contain
cell
bm
graft
limit
concern
increas
gvhd
although
differ
gvhd
found
haplohct
epidemiolog
incid
infecti
diseas
complic
associ
haplohct
incomplet
understood
largest
studi
date
consist
patient
undergo
bm
haplohct
ptci
report
moder
incid
cytomegaloviru
cmv
reactiv
peak
earli
postengraft
period
bacteri
infect
highest
preengraft
period
half
patient
least
one
bacteri
infect
matchedrel
donor
mrd
allogen
transplant
pbsc
graft
associ
increas
earli
cmv
reactiv
decreas
rate
bacteri
fungal
infect
compar
bm
graft
meanwhil
matchedunrel
donor
allogen
transplant
pbsc
graft
associ
significantli
fewer
infecti
complic
limit
inform
avail
concern
pbsc
haplohct
studi
describ
epidemiolog
infecti
complic
associ
haplohct
use
ptci
pbsc
graft
patient
receiv
peripher
mobil
hematopoiet
cell
graft
donor
select
hla
type
match
grade
rang
optim
donor
determin
order
lack
donorspecif
antibodi
recipi
cmv
serostatu
match
donor
health
statu
donor
mobil
granulocyt
colonystimul
factor
gcsf
graft
cell
count
character
use
flow
cytometri
target
dose
cellskg
tcell
deplet
use
patient
receiv
mgkg
ptci
day
mycophenol
mofetil
either
tacrolimu
sirolimu
start
day
unless
contraind
patient
receiv
herpesviru
pneumocysti
fungal
prophylaxi
standard
herpesviru
prophylaxi
mg
acyclovir
three
time
day
tid
mg
valacyclovir
daili
qd
day
cessat
immunosuppress
patient
discharg
ganciclovir
gcv
cmv
treatment
transit
standard
herpesviru
prophylaxi
follow
complet
treatment
primari
fungal
prophylaxi
mg
fluconazol
qd
day
patient
histori
invas
fungal
infect
ifi
discharg
antifung
treatment
receiv
secondari
prophylaxi
continu
cessat
immunosuppress
pneumocysti
prophylaxi
given
day
consist
trimethoprimsulfamethoxazol
dapson
atovaquon
institut
patient
activ
screen
vancomycinresist
enterococcu
vre
colon
whole
blood
cmv
polymeras
chain
reaction
pcr
test
perform
twice
weekli
transplant
hospit
weekli
day
subsequ
monitor
determin
patient
physician
patient
receiv
antivir
treatment
cmv
diseas
consecut
doubl
blood
dna
level
pcr
signific
viremia
defin
iuml
approxim
equival
level
altern
pcr
assay
use
standard
descript
statist
use
character
studi
popul
evalu
distribut
variabl
none
variabl
interest
normal
distribut
median
rang
use
central
tendenc
dispers
continu
variabl
chisquar
test
fisher
exact
test
appropri
use
evalu
distribut
categor
variabl
mannwhitney
utest
use
compar
distribut
continu
variabl
surviv
analysi
conduct
logrank
test
identifi
patient
inclus
studi
shown
tabl
cohort
contain
larg
number
highrisk
patient
acut
myeloid
leukemia
common
diagnosi
twentyseven
percent
patient
receiv
previou
hct
activ
diseas
transplant
major
underw
one
three
previous
describ
condit
regimen
figur
b
diseas
associ
pathogen
class
summar
sixteen
patient
experienc
cmvassoci
endorgan
diseas
affect
gut
case
lung
case
case
one
case
involv
retina
mening
lung
seven
fungal
infect
diagnos
followup
period
six
classifi
proven
accord
eortcmsg
criteria
via
blood
cultur
biopsi
autopsi
posit
blood
cultur
candida
zygomycet
speci
dissemin
mucormycosi
found
kidney
lung
one
patient
die
follow
stroke
patient
develop
fungal
infect
transplant
hospit
die
discharg
one
infect
classifi
probabl
galactomannan
assay
cavitari
nodul
chest
comput
tomographi
pneumocysti
infect
observ
nineteen
patient
discharg
initi
hospit
receiv
either
secondari
prophylaxi
voriconazol
therapeut
antifung
treatment
one
patient
later
develop
fungal
infect
followup
period
patient
die
per
publish
criteria
common
primari
cod
relaps
follow
gvhd
primari
contribut
cod
period
infecti
risk
summar
tabl
infect
primari
cod
infect
contribut
cod
addit
analysi
describ
infecti
complic
patient
receiv
pb
haplohct
ptci
overal
infect
primari
contribut
cod
half
patient
die
patientday
observ
slightli
higher
rate
earli
bacteri
infect
markedli
higher
rate
earli
viral
infect
figur
note
patient
report
crocchiolo
et
al
receiv
routin
bacteri
prophylaxi
levofloxacin
wherea
median
time
neutrophil
engraft
shorter
vs
day
differ
may
skew
attribut
infect
preengraft
period
despit
neutrophil
recoveri
particular
larg
number
viral
infect
occur
neutrophil
engraft
day
figur
vs
b
observ
rate
ifi
increas
earli
cmv
reactiv
consist
previou
literatur
compar
pbsc
bm
graft
also
observ
high
incid
earli
neutropen
fever
cohort
associ
pb
haplohct
postinfus
fever
increasingli
recogn
literatur
high
incid
enterococc
infect
popul
notabl
find
colon
vre
associ
later
infect
consist
previous
publish
work
associ
enterococc
infect
earli
mortal
contrast
observ
aureu
infect
similar
previou
report
allogen
hct
observ
rate
cdi
compar
previous
report
rate
rate
recurr
infect
high
proport
earlyonset
cdi
report
literatur
associ
cdi
gastrointestin
gvhd
also
note
observ
popul
cdi
discern
impact
surviv
role
graft
sourc
cmv
infect
still
matter
debat
mrd
set
young
et
al
found
differ
cmv
infect
within
larg
retrospect
cohort
patient
undergo
hct
either
bm
pbsc
howev
earli
cmv
reactiv
higher
rate
reactiv
diseas
patient
receiv
pbsc
graft
report
guerrero
et
al
analyz
cohort
mrd
patient
random
pbsc
bm
graft
found
alter
preval
prolifer
cmvspecif
cell
follow
gcsf
mobil
compar
previous
publish
data
bm
haplohct
rate
cmv
viremia
associ
previou
donor
andor
recipi
cmv
seroposit
cmv
diseas
consider
higher
vs
vs
rate
cmv
viremia
among
seroposit
recipi
similar
anoth
cohort
pbsc
haplohct
patient
vs
although
incid
cmv
diseas
consider
higher
vs
associ
earli
viremia
recipi
cmv
pretranspl
seroposit
cmv
diseas
consist
alter
cmv
immun
set
may
indic
need
altern
approach
treatment
cmv
viremia
popul
also
observ
rel
high
rate
hsv
prophylaxi
failur
especi
among
patient
seroposit
observ
low
rate
incid
ifi
cohort
similar
previous
report
rate
haplohct
bm
graft
low
rate
may
reflect
efficaci
receiv
extend
primari
antifung
prophylaxi
day
rel
larg
proport
patient
receiv
secondari
fungal
prophylaxi
inclus
probabl
proven
fungal
infect
consist
literatur
like
result
underestim
true
incid
fungal
infect
popul
followup
time
cohort
also
limit
may
also
contribut
underestim
fungal
infect
often
occur
later
patient
cgvhd
studi
sever
limit
first
exclud
suspect
infect
microbiolog
confirm
underestim
true
incid
infect
popul
febril
episod
identifi
organ
common
occurr
popul
furthermor
mani
patient
suspect
pneumonia
undergo
bronchoscopi
owe
thrombocytopenia
howev
employ
strict
criteria
result
specif
reli
retrospect
clinic
judgment
second
studi
includ
comparison
group
make
contextu
report
rate
infect
difficult
especi
given
region
variat
pathogen
howev
also
allow
us
provid
extrem
broad
comprehens
descript
infecti
experi
within
novel
cohort
pathogenspecif
compar
studi
direct
futur
research
may
help
illumin
differ
immun
reconstitut
follow
haplohct
compar
tradit
donor
third
limit
collect
data
medic
record
system
gener
patient
receiv
transplantrel
care
institut
case
acut
ill
patient
like
receiv
treatment
closer
home
episod
would
captur
studi
howev
patient
usual
transfer
institut
hospit
data
captur
overal
data
repres
conserv
estim
infecti
experi
popul
knowledg
cohort
repres
largest
analysi
